Page last updated: 2024-12-05

isoproterenol hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5807
CHEMBL ID1711
CHEBI ID31453
SCHEMBL ID7627
MeSH IDM0011782

Synonyms (193)

Synonym
isomenyl
nsc89747
(.+-.)-isoprenaline hydrochloride
(.+-.)-isoproterenol hydrochloride
dl-isopropylnorepinephrine hydrochloride
dl-isadrine hydrochloride
1, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-, hydrochloride, (.+-.)-
949-36-0
(+-)-isopropylnoradrenaline hydrochloride
benzyl alcohol,4-dihydroxy-.alpha.-[(isopropylamino)methyl]-, hydrochloride, (+-)-
nsc-89747
dl-isoprenaline hydrochloride
(+-)-isoproterenol hydrochloride
1, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-, hydrochloride, (+-)-
benzyl alcohol,4-dihydroxy-.alpha.-[(isopropylamino)methyl]-, hydrochloride, (.+-.)-
iprenol
dl-isopropylnoradrenaline hydrochloride
(+-)-isoprenaline hydrochloride
(.+-.)-isopropylnoradrenaline hydrochloride
dl-isoproterenol hydrochloride
MLS002153386
isopropylnorepinephrine-hydrochloride
component of aerolone compound
isadrine-hydrochloride
51-30-9
benzyl alcohol,4-dihydroxy-.alpha.-[(isopropylamino)methyl]-, hydrochloride
izadrin
norisodrine hydrochloride
sooner
1, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-, hydrochloride
vapo-iso
.alpha.-(isopropylaminomethyl)-3,4-dihydroxybenzyl alcohol hydrochloride
aerolone
aerotrol
isoproterenol hydrochloride
isopropylarterenol hydrochloride
nsc-37745
isoprenaline hydrochloride
nci-c55630
isuprel hydrochloride
wln: qr bq dyq1my1&1 &gh
3,4-dihydroxy-.alpha.-[(isopropylamino)methyl]benzyl alcohol hydrochloride
isoproterenol monohydrochloride
nsc37745
EU-0100711
l-isoprenaline hydrochloride
nsc 89747
isuprel
euspiran
MLS001335894
MLS001335893
NCGC00025274-02
benzenemethanol, 3,4-dihydroxy-alpha-(((1-methylethyl)amino)methyl)-, hydrochloride, (+/-)-
nsc 37745
ccris 5921
isoprenaline chloride
isoprenaline hydrochloride (van)
norisodrine aerotrol
einecs 200-089-8
ai3-52675
asthpul
alpha-(isopropylaminomethyl)-3,4-dihydroxybenzyl alcohol hydrochloride
3,4-dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol hydrochloride
1,2-benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, hydrochloride
benzyl alcohol, 3,4-dihydroxy-alpha-((isopropylamino)methyl)-, hydrochloride
proternol-s (tn)
dl-isoprenaline hydrochloride (jan)
isuprel (tn)
D01390
isoproterenol hydrochloride (usp)
NCGC00025274-05
NCGC00094061-02
NCGC00094061-03
SPECTRUM1500357
isoproterenol hcl
4-[1-hydroxy-2-(isopropylamino)ethyl]benzene-1,2-diol hydrochloride
MLS001304049
NCGC00094033-02
NCGC00094061-04
smr000058267
NCGC00094061-01
(?)-isoproterenol hydrochloride
NCGC00094033-01
hydrochloride, isoproterenol
I 5627
( inverted question mark)-isoproterenol hydrochloride
VU0244462-4
CHEMBL1711
isovon
mistarel
isoprenaline hydrochloride, dl-
suscardia
I0260
HMS1920H13
HMS1571K16
dia2a74855 ,
isoproterenol hydrochloride [usp]
unii-dia2a74855
dtxsid6025486 ,
tox21_201272
NCGC00254027-01
dtxcid105486
tox21_300308
NCGC00258824-01
cas-51-30-9
1,2-benzenediol, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-, hydrochloride;isoprenaline hcl
A828528
pharmakon1600-01500357
nsc-757079
nsc757079
isoprenaline hcl
CCG-40129
BCP9000796
1-(3',4'-dihydroxyphenyl)-2-isopropylaminoethanol hydrochloride
niosh/ux1780000
UX17800000
pyrocatechol, 4-(1-hydroxy-2-(isopropylamino)ethyl)-, hydrochloride
4-(1-hydroxy-2-(isopropylamino)ethyl)pyrocatechol hydrochloride
BCP0726000230
FT-0635930
FT-0627456
LP00711
(+/-)-isoproterenol hydrochloride
AKOS015895437
S2566
isoprenaline hydrochloride [ep impurity]
isoproterenol hydrochloride [vandf]
dl-isoprenaline hydrochloride [jan]
isoproterenol hydrochloride component of duo-medihaler
isoprenaline hydrochloride [who-ip]
isoproterenol hydrochloride [usp-rs]
duo-medihaler component isoproterenol hydrochloride
isoproterenol hydrochloride [usp monograph]
isoprenaline hydrochloride [mart.]
isoprenaline hydrochloride [who-dd]
1336-89-6
isoproterenol hydrochloride [orange book]
isoprenaline hydrochloride [ep monograph]
isoproterenol dl-form hydrochloride [mi]
3,4-dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol hydrochloride
HY-B0468
isoprenaline (hydrochloride)
NC00515
SCHEMBL7627
IROWCYIEJAOFOW-UHFFFAOYSA-N
4-(1-hydroxy-2-(isopropylamino)ethyl)benzene-1,2-diol hydrochloride
NCGC00261396-01
tox21_500711
(y)-isoproterenol hydrochloride
REGID_FOR_CID_5807
4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol hydrochloride
W-105908
4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-1,2-benzenediol hydrochloride
isoproterenolhydrochloride
mfcd00012603
4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol;hydrochloride
AC-8688
SR-01000075272-1
sr-01000075272
isoproterenol hydrochloride, united states pharmacopeia (usp) reference standard
isoprenaline hydrochloride, european pharmacopoeia (ep) reference standard
CHEBI:31453
SR-01000075272-3
SW197212-2
isoprenaline hydrochloride,(s)
Q26840880
AS-13330
BCP23375
levisoprenaline (hydrochloride)
isoproterenol (hydrochloride)
H10806
4-(1-hydroxy-2-(isopropylamino)ethyl)benzene-1,2-diol hcl
EN300-108428
Z1416254508
isovon (cl)
izadrine-hydrochloride
isoprenaline hydrochloride (ep impurity)
proternol-s
4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol hydrochloride
3,4-dihydroxy-alpha-((isopropylamino)methyl)-benzyl alcohol hydrochloride
isoprel
isoproterenol dl-form hydrochloride
isoprenaline hydrochloride (ep monograph)
1-(3,4-dihydroxyphenyl)-2-(isopropylamino)ethanol hydrochloride
isoprenaline hydrochloride (mart.)
aludrine hydrochloride
norisodrine-h
isoproterenol hydrochloride (usp monograph)
4-(1-hydroxy-2-((methylethyl)amino)ethyl)-1,2-benzenediol hydrochloride
isopropydrine hydrochloride
3,4-dihydroxy-alpha-(isopropylaminomethyl)benzyl alcohol hydrochloride
isoproterenol hydrochloride (usp-rs)
isointranefrin

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
catecholsAny compound containing an o-diphenol component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (51)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency7.07950.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency28.18380.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency6.31900.140911.194039.8107AID2451; AID2787
Chain A, HADH2 proteinHomo sapiens (human)Potency0.12590.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency0.12590.025120.237639.8107AID886
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency14.69990.177814.390939.8107AID2147
interleukin 8Homo sapiens (human)Potency0.06680.047349.480674.9780AID651758
endonuclease IVEscherichia coliPotency44.66840.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency45.59950.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency7.24010.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency2.81840.180013.557439.8107AID1460
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency31.62280.707912.194339.8107AID720542
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.39810.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency60.57160.001022.650876.6163AID1224838; AID1224893
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency39.81070.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.03160.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency64.06940.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency20.01290.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.98220.001530.607315,848.9004AID1224820; AID1224821; AID1224841; AID1224842; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency35.48130.005428.02631,258.9301AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.63490.000229.305416,493.5996AID1259244; AID743069; AID743078
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency24.54120.001024.504861.6448AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency13.80060.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.70790.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency57.80670.000723.06741,258.9301AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.00580.001628.015177.1139AID1224843; AID1224895; AID1259393
Histone H2A.xCricetulus griseus (Chinese hamster)Potency56.62520.039147.5451146.8240AID1224845
beta-2 adrenergic receptorHomo sapiens (human)Potency2.42380.00586.026332.6427AID492947; AID588463; AID588790
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00790.540617.639296.1227AID2364; AID2528
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency3.16230.036619.637650.1187AID2100
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency80.303923.934123.934123.9341AID1967
fructose-bisphosphate aldolase AOryctolagus cuniculus (rabbit)Potency0.79430.891316.576239.8107AID2794
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency0.76673.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency67.75340.000323.4451159.6830AID743065
DNA polymerase betaHomo sapiens (human)Potency44.66840.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.08970.039816.784239.8107AID995
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency17.75860.000627.21521,122.0200AID651741; AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency0.01410.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
relaxin receptor 1 isoform 1Homo sapiens (human)Potency3.16230.038814.350143.6206AID2676
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.58960.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.50110.00000.66359.5499AID637822
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
beta-2 adrenergic receptorHomo sapiens (human)EC50 (µMol)0.82500.00161.87598.4400AID588763
Beta-2 adrenergic receptorHomo sapiens (human)EC50 (µMol)0.15220.00000.311110.0000AID1650066; AID637823; AID637886
Beta-1 adrenergic receptorHomo sapiens (human)EC50 (µMol)0.00150.00010.49146.0000AID1650067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-1 adrenergic receptor Cavia porcellus (domestic guinea pig)ED250.00340.00340.00460.0071AID1135294
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (57)

Assay IDTitleYearJournalArticle
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID698396Selectivity ratio of apparent dissociation constant for enzyme-inhibitor complex for human AChE to apparent dissociation constant for enzyme-inhibitor complex for human BChE usual homozygous variant2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
AID698394Selectivity ratio of apparent dissociation constant for enzyme-inhibitor complex for human AChE to apparent dissociation constant for enzyme-inhibitor complex for human BChE T243M/G390V mutant fluoride-resistant homozygous variant2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
AID1650066Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β
AID637822Displacement of [3H]-DHA from recombinant human beta2 adrenoceptor expressed in HEK293T cells2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID698393Selectivity ratio of apparent dissociation constant for enzyme-inhibitor complex for human AChE to apparent dissociation constant for enzyme-inhibitor complex for human BChE D70G mutant usual-atypical heterozygous variant2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
AID637823Agonist activity at recombinant human beta2 adrenoceptor expressed in HEK293T cells assessed as increase in IBMX-induced cAMP accumulation using [3H]-cAMP after 30 mins by liquid scintillation counting2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1650069Partial agonist activity at human beta2 adrenoreceptor endogenously expressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β
AID698400Reversible inhibition of human BChE D70G mutant atypical homozygous variant using propionylthiocholine as substrate assessed as apparent dissociation constant for enzyme-inhibitor complex2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
AID1135303Selectivity ratio of ED50 for beta-2 adrenergic receptor in guinea pig trachea over ED50 for beta-1 adrenergic receptor in guinea pig atria1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Adrenergic agents. 4. Substituted phenoxypropanolamine derivatives as potential beta-adrenergic agonists.
AID1135294Agonist activity at beta-1 adrenergic receptor in guinea pig atria assessed as increase in rate of contraction of spontaneously beating right atria1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Adrenergic agents. 4. Substituted phenoxypropanolamine derivatives as potential beta-adrenergic agonists.
AID1136961Cardiac stimulant activity in iv dosed dog assessed as increase in heart rate1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Conformational analogues of dopamine. Synthesis and pharmacological activity of (E)- and (Z)-2-(3,4-dihydroxyphenyl)cyclopropylamine hydrochlorides.
AID1650072Agonist activity at beta2 adrenergic receptor in Dunkin-Hartley guinea pig trachea assessed as reduction in histamine-induced muscle contraction by measuring onset time2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β
AID698399Reversible inhibition of human BChE T243M/G390V mutant fluoride-resistant homozygous variant using propionylthiocholine as substrate assessed as apparent dissociation constant for enzyme-inhibitor complex2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
AID1650068Selectivity index, ratio of pEC50 for human beta1 adrenoreceptor overexpressed in human HEK293 cells subtracted from pEC50 for human beta2 adrenoreceptor overexpressed in human HEK293 cells2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID637886Agonist activity at recombinant human beta2 adrenoceptor expressed in DU145 cells assessed as increase in cAMP accumulation2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID698395Selectivity ratio of apparent dissociation constant for enzyme-inhibitor complex for human AChE to apparent dissociation constant for enzyme-inhibitor complex for human BChE D70G mutant atypical homozygous variant2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID698392Binding affinity to human BChE D70G mutant atypical homozygous variant relative to terbutaline2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
AID698398Reversible inhibition of human BChE D70G mutant usual-atypical heterozygous variant using propionylthiocholine as substrate assessed as apparent dissociation constant for enzyme-inhibitor complex2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
AID1136960Cardiac stimulant activity in iv dosed dog assessed as dose producing 50% increase in contractile force1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Conformational analogues of dopamine. Synthesis and pharmacological activity of (E)- and (Z)-2-(3,4-dihydroxyphenyl)cyclopropylamine hydrochlorides.
AID1135292Agonist activity at beta-2 adrenergic receptor in guinea pig trachea assessed as relaxation of spontaneously contracted muscle1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Adrenergic agents. 4. Substituted phenoxypropanolamine derivatives as potential beta-adrenergic agonists.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID698401Reversible inhibition of human BChE usual homozygous variant using propionylthiocholine as substrate assessed as apparent dissociation constant for enzyme-inhibitor complex2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
AID328838Suppression of aggregation of poly Q102-GFP protein expressed in zebrafish embryo at 10 uM by filter trap assay2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model.
AID1135302Intrinsic activity at beta-1 adrenergic receptor in guinea pig atria assessed as increase in rate of contraction of spontaneously beating right atria relative to isoproterenol1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Adrenergic agents. 4. Substituted phenoxypropanolamine derivatives as potential beta-adrenergic agonists.
AID698397Reversible inhibition of human AChE using acetylthiocholine as substrate assessed as apparent dissociation constant for enzyme-inhibitor complex2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors.
AID1650067Agonist activity at human beta1 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β
AID1650070Agonist activity at beta2 adrenergic receptor in Dunkin-Hartley guinea pig trachea assessed as reduction in histamine-induced muscle contraction2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β
AID1650071Agonist activity at beta2 adrenergic receptor in Dunkin-Hartley guinea pig trachea assessed as reduction in histamine-induced muscle contraction relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (8.00)18.7374
1990's0 (0.00)18.2507
2000's4 (16.00)29.6817
2010's14 (56.00)24.3611
2020's5 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.52 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (96.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]